FR3056592B1 - Composes pour leur utilisation en imagerie et notamment pour le diagnostic de maladies neuro-degeneratives - Google Patents

Composes pour leur utilisation en imagerie et notamment pour le diagnostic de maladies neuro-degeneratives Download PDF

Info

Publication number
FR3056592B1
FR3056592B1 FR1659033A FR1659033A FR3056592B1 FR 3056592 B1 FR3056592 B1 FR 3056592B1 FR 1659033 A FR1659033 A FR 1659033A FR 1659033 A FR1659033 A FR 1659033A FR 3056592 B1 FR3056592 B1 FR 3056592B1
Authority
FR
France
Prior art keywords
neuro
diagnosis
imaging
compounds
degenerative diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1659033A
Other languages
English (en)
Other versions
FR3056592A1 (fr
Inventor
Sylvain Routier
Franck Suzenet
Sylvie Chalon
Frederic BURON
Johnny Vercouillie
Ronald MELKI
Liliana BOIARYNA
Denis Guilloteau
Laura PIERI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Regional Universitaire de Tours
Universite d Orleans UFR de Sciences
Universite de Tours
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Francois Rabelais de Tours
Centre Hospitalier Regional Universitaire de Tours
Universite d Orleans UFR de Sciences
Universite de Tours
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Francois Rabelais de Tours, Centre Hospitalier Regional Universitaire de Tours, Universite d Orleans UFR de Sciences, Universite de Tours filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1659033A priority Critical patent/FR3056592B1/fr
Priority to US16/336,309 priority patent/US10906900B2/en
Priority to EP17783941.2A priority patent/EP3515912B1/fr
Priority to PCT/FR2017/052592 priority patent/WO2018055316A1/fr
Publication of FR3056592A1 publication Critical patent/FR3056592A1/fr
Application granted granted Critical
Publication of FR3056592B1 publication Critical patent/FR3056592B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1659033A 2016-09-26 2016-09-26 Composes pour leur utilisation en imagerie et notamment pour le diagnostic de maladies neuro-degeneratives Expired - Fee Related FR3056592B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1659033A FR3056592B1 (fr) 2016-09-26 2016-09-26 Composes pour leur utilisation en imagerie et notamment pour le diagnostic de maladies neuro-degeneratives
US16/336,309 US10906900B2 (en) 2016-09-26 2017-09-26 Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases
EP17783941.2A EP3515912B1 (fr) 2016-09-26 2017-09-26 Composes pour leur utilisation en imagerie et notamment pour le diagnostic de maladies neuro-degeneratives
PCT/FR2017/052592 WO2018055316A1 (fr) 2016-09-26 2017-09-26 Composes pour leur utilisation en imagerie et notamment pour le diagnostic de maladies neuro-degeneratives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1659033 2016-09-26
FR1659033A FR3056592B1 (fr) 2016-09-26 2016-09-26 Composes pour leur utilisation en imagerie et notamment pour le diagnostic de maladies neuro-degeneratives

Publications (2)

Publication Number Publication Date
FR3056592A1 FR3056592A1 (fr) 2018-03-30
FR3056592B1 true FR3056592B1 (fr) 2018-11-16

Family

ID=57396670

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1659033A Expired - Fee Related FR3056592B1 (fr) 2016-09-26 2016-09-26 Composes pour leur utilisation en imagerie et notamment pour le diagnostic de maladies neuro-degeneratives

Country Status (1)

Country Link
FR (1) FR3056592B1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521988A (ja) * 2009-03-23 2012-09-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経学的障害を検知するためのイメージング剤
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders

Also Published As

Publication number Publication date
FR3056592A1 (fr) 2018-03-30

Similar Documents

Publication Publication Date Title
EP3731868A4 (fr) Anticorps anti-tigit et leur utilisation comme agents thérapeutiques et diagnostiques
EP3337465A4 (fr) Compositions et méthodes d'utilisation en association destinées au traitement et au diagnostic de maladies auto-immunes
EP3641644A4 (fr) Système et procédé de diagnostic médical
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP2986210A4 (fr) Biomarqueurs d'imagerie pour le diagnosti de douleurs de dos
EP3710831A4 (fr) Marqueurs pour le diagnostic et le traitement de la stéatohépatite non alcoolique (nash) et de la fibrose hépatique avancée
EP3294143A4 (fr) Systèmes et procédés pour l'imagerie de structures de tissu biologique
EP3411505A4 (fr) Détection et diagnostic d'évolution d'un cancer
EP3482201A4 (fr) Diagnostic précoce d'infections
EP2946211A4 (fr) Procédés et compositions pour le diagnostic et le pronostic de lésion rénale et d'insuffisance rénale
MA43980A (fr) Méthodes de diagnostic et de pronostic de maladies et d'événements cardiovasculaires
EP3490677A4 (fr) Marqueurs lipidiques, protéiques et métaboliques pour le diagnostic et le traitement du cancer de la prostate
EP3294142A4 (fr) Systèmes et procédés pour l'imagerie de structures de tissu biologique
EP3484487A4 (fr) Échafaudages de biomatrice pour utilisation dans le diagnostic et la modélisation de cancer
EP3365459A4 (fr) Procédés et dispositifs améliorés pour un diagnostic précis d'infections
EP3735970C0 (fr) Cébranopadol pour le traitement de la douleur chez des sujets à fonction hépatique altérée et/ou fonction rénale altérée
EP3123176A4 (fr) Diagnostic de la sclérose en plaques chez des sujets humains et animaux
EP3347492A4 (fr) Procédés pour le diagnostic histologique et le traitement de maladies
LT3787576T (lt) Viso kūno hipertermijos sistema
EP3692892A4 (fr) Système de diagnostic d'imagerie ophtalmique
EP3646795A4 (fr) Cathéter de diagnostic d'image
EP3356863A4 (fr) Fantôme d'imagerie et ses systèmes et procédés d'utilisation
EP3646796A4 (fr) Cathéter de diagnostic d'image
EP3472181A4 (fr) Méthodes pour le diagnostic et le traitement de maladies auto-immunes

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180330

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20230505